Henlius Biopharmaceuticals
China - ShanghaiPharmaceutical
Focus: Henlius is a Shanghai-based biosimilar-focused pharmaceutical company founded in 2019 with 201-500 employees. The company operates in the biosimilar space with early-stage pipeline assets.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Employees
201-500
Open Jobs
0
About Henlius Biopharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Henlius Biopharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
HLX70
COVID-19Clinical Trials (1)
NCT05429385Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Phase 1Help build intelligence for Henlius Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.